Cross-sectional study reveals procalcitonin as a potential biomarker in rosacea, suggesting implications for systemic therapy.
PCT may reflect underlying subclinical inflammation in rosacea and decrease with systemic therapy. These findings support further investigation of PCT as a biomarker in rosacea.
No takes yet. Share an insight, caveat, or question.
Benar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: